First clinical proof-of-concept of CAR T-cell combination therapy: The phase 2, single-arm ZUMA-14 trial of axicabtagene ciloleucel in combination with rituximab for refractory large B-cell lymphoma
In this study, researchers looked at how safe and well axi-cel and rituximab worked to treat people with refractory large B-cell lymphoma. These therapies target 2 different markers on the surface of the cancer cell. The study showed that this dual-targeting strategy is feasible and generally safe.
